CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Louisville, Kentucky, United States and 175 other locations
The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...
Phase 3
Louisville, Kentucky, United States and 179 other locations
The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...
Phase 3
Louisville, Kentucky, United States and 86 other locations
The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely co...
Phase 1, Phase 2
Louisville, Kentucky, United States and 49 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...
Phase 3
Louisville, Kentucky, United States and 231 other locations
ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic...
Phase 1, Phase 2
Louisville, Kentucky, United States and 38 other locations
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...
Phase 3
Louisville, Kentucky, United States and 170 other locations
with obinutuzumab (Arm B) for the treatment of previously untreated chronic lymphocytic leukemia (CLL). Secondary objectiv...
Phase 3
Louisville, Kentucky, United States and 154 other locations
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart...
Phase 1
Louisville, Kentucky, United States and 57 other locations
This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic...
Phase 1
Louisville, Kentucky, United States and 16 other locations
Clinical trials
Research sites
Resources
Legal